Black Diamond Therapeutics, Inc. (BDTX)
Last updated: 2026-10-21 16:15:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Summary
Black Diamond Therapeutics, Inc. (BDTX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $2.03, with a market capitalization of $103.99M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.60 to $4.94. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$103.99M | |
$2.07 | |
$46.25 | |
$1.18 | |
$2.07 | |
959.48K | |
643.02K | |
-- | |
$4.94 | |
$1.60 | |
-- | |
-- |
Black Diamond Therapeutics, Inc. (BDTX) Stock Price Today
Black Diamond Therapeutics, Inc. (BDTX) is currently trading at $2.03 as of 2026-10-21 16:13:00, down 2.17% ($0.04) from the previous close of $2.07
During today's regular trading session, BDTX has traded between $1.18 and $46.25, with a trading volume of 959.48K shares. The current price is near the lower end of today's range.
Black Diamond Therapeutics, Inc. (BDTX) 7-Day Stock Price Change
Over the past seven days, Black Diamond Therapeutics, Inc. (BDTX) moved from $1.77 to $2.03, representing a gain of 14.41% ($0.25).
The stock traded between $1.60 and $2.14 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 956.00 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
BDTX 52-Week Price Position
Position in Range: 12.7%
BDTX is currently trading at $2.03, placing it 12.7% of the way from its 52-week low of $1.60 to its 52-week high of $4.94. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Black Diamond Therapeutics, Inc. (BDTX)?
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Black Diamond Therapeutics, Inc. Information
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 21 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Black Diamond Therapeutics, Inc. (BDTX) Stock on MEXC
Eligible investors can buy real shares of Black Diamond Therapeutics, Inc. (BDTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Black Diamond Therapeutics, Inc. (BDTX) stock price today?
2.Is BDTX stock going up or down today?
3.What is BDTX pre-market price?
4.What is BDTX after-hours price?
5.Is BDTX stock trading now?
6.Where does BDTX sit relative to its 52-week high and low?
7.What sector is Black Diamond Therapeutics, Inc. in?
8.What is Black Diamond Therapeutics, Inc.'s market capitalization and where is it listed?
9.How is BDTX valued in terms of P/E ratio and EPS?
10.Does Black Diamond Therapeutics, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
BDTX Stock Calculator
Estimate the value between BDTX shares and USD.
BDTX Shares to USD
1.00 BDTX shares = 2.025 USD
Calculations are estimates based on the latest available price and are for reference only.


